Australian middle-market private equity firm CPE has agreed to sell cord blood banking business Cell Care to Generate Life Sciences, a US-based provider of cellular services for fertility and therapeutic purposes.
The size of the transaction was not disclosed but the Australian Financial Review reported that it valued Cell Care at approximately A$200 million ($153 million). It still requires approval from the Australian...
Australia’s Go1 gains traction with a B2B approach to a rapidly expanding human resources and workforce management software industry. SoftBank Vision Fund 2 is among the believers
Having agreed to provide a succession solution to the founder of Korean furniture retailer and interior designer Hanssem, IMM Private Equity wants to harness growth through demographics and differentiation
The lack of a reliable IPO channel is a longstanding exit obstacle for venture capital investors in India. Domestic listings may, unexpectedly, prove to be the answer
Semiconductors are a popular investment target in China on the back of US decoupling and a push for self-sufficiency. Alex Banh, a managing partner of sector specialist IPV Capital, shares his views